Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen (FLUID)


May, 2019

Clinical Trial

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ.

Ophthalmology. 2019 May;126(5):723-734.
Full text | Metrics.

Share This Article :

Updated on March 7th, 2022

Source Archive